Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Compugen Ltd. (CGEN) Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Compugen Ltd. (CGEN)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Life Sciences Tools & Services
Competitors: BRKR, INCR, PRAH, LMNX

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

Compugen Ltd.© quotemedia

Company Profile

Compugen Ltd., a therapeutic product discovery company, focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. Its discovery efforts consist of in silico (by computer) product candidate prediction and selection followed by experimental validation. The company’s therapeutic proteins comprise CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein to treat multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases. Its monoclonal antibody target product candidates include CGEN-671, a drug for multiple epithelial tumors; CGEN-928, a drug for multiple myeloma; and CGEN-15001T, a novel B7/CD28 family member; and CGEN-15022 and CGEN-15092 for cancer immunotherapy. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.

Recent News: Compugen Ltd.